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Contrasting beneﬁts of different artemisinin
combination therapies as ﬁrst-line malaria
treatments using model-based cost-effectiveness
analysis
Lucy C. Okell1, Matthew Cairns2, Jamie T. Grifﬁn1, Neil M. Ferguson1, Joel Tarning3,4, George Jagoe5,
Pierre Hugo5, Mark Baker5, Umberto D’Alessandro6,7,8, Teun Bousema9, David Ubben5 & Azra C. Ghani1
There are currently several recommended drug regimens for uncomplicated falciparum
malaria in Africa. Each has different properties that determine its impact on disease
burden. Two major antimalarial policy options are artemether–lumefantrine (AL) and
dihydroartemisinin–piperaquine (DHA–PQP). Clinical trial data show that DHA–PQP provides
longer protection against reinfection, while AL is better at reducing patient infectiousness.
Here we incorporate pharmacokinetic-pharmacodynamic factors, transmission-reducing
effects and cost into a mathematical model and simulate malaria transmission and treatment
in Africa, using geographically explicit data on transmission intensity and seasonality,
population density, treatment access and outpatient costs. DHA–PQP has a modestly higher
estimated impact than AL in 64% of the population at risk. Given current higher cost
estimates for DHA–PQP, there is a slightly greater cost per case averted, except in areas with
high, seasonally varying transmission where the impact is particularly large. We ﬁnd that a
locally optimized treatment policy can be highly cost effective for reducing clinical malaria
burden.
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A
rtemisinin-based combination therapies (ACT) are the
ﬁrst-line-recommended treatments for uncomplicated
Plasmodium falciparum malaria across nearly all malaria-
endemic countries. The artemisinin derivative in the combination
rapidly kills parasites but has a short half-life, while a partner drug
with a longer half-life is given to clear remaining parasites
after the artemisinin is no longer present. Five ACTs are currently
recommended by the World Health Organization1: artemether–
lumefantrine (AL), artesunate–amodiaquine (AS–AQ), artesunate–
meﬂoquine (AS–MQ), artesunate–sulfadoxine–pyrimethamine
(AS–SP) and, more recently, dihydroartemisinin–piperaquine
(DHA–PQP). While the majority of countries recommend a
single ﬁrst-line treatment, several countries have either introduced
or are considering multiple ﬁrst-line therapies2. To date, choice
of therapy has been based predominantly on cure rates for
individuals (including assessment of existing drug resistance) and
cost. However, now that many countries are aiming to
substantially reduce malaria burden, the ability of the drug to
reduce transmission is increasingly relevant3. Two properties of
antimalarials can impact on transmission—(a) their ability to
reduce onward transmission by rapidly killing circulating parasites
and (b) the length of time for which the drug reduces the chance of
reinfection. Understanding how these properties translate into
impact and cost effectiveness can help countries choose optimal
treatments for local populations.
Antimalarial drugs with long half-lives continue to beneﬁt the
patient after cure is achieved through post-treatment prophylaxis;
that is, by protecting them against reinfection while the drug
remains in the bloodstream. In areas with high malaria
transmission and hence frequent re-exposure, this may be
particularly important and could reduce malaria transmission
within the whole community as well as protect individual
patients, since preventing new infections also prevents future
transmission4,5. Antimalarials that reduce a patient’s
infectiousness likewise beneﬁt the community. Any efﬁcacious
antimalarial reduces the duration of infectiousness compared
with an untreated or partially treated infection by killing asexual
parasites, the source of gametocytes which are the transmissible
life stage of the parasite. Drugs with gametocytocidal action
further reduce the duration of infectiousness. Gametocytocidal
drugs may be effective only during part of the parasite life cycle;
for example, artemisinin derivatives act against immature
gametocytes but are not effective against late-stage gametocytes6.
DHA–PQP has recently been introduced into national guide-
lines as an option for ﬁrst- or second-line treatment in several
African countries, including Ghana, Senegal, Kenya and Nigeria,
and is in trials in several further countries. AL currently dominates
the antimalarial market, comprising 77% of the 331 million ACT
treatments used in 2012 (ref. 7). AS–AQ and AS–SP are also used
for ﬁrst-line treatment in some African countries but are not
suitable for all areas due to resistance to the partner drugs. AS–MQ
has not had wide uptake in Africa and is not included in the
treatment policy of any sub-Saharan African country7. We
therefore focus on contrasting DHA–PQP with AL as a ﬁrst-line
treatment option. The piperaquine component of DHA–PQP has a
longer half-life than lumefantrine8, therefore DHA–PQP is likely to
provide greater post-treatment prophylaxis, although the duration
of protection is not known. A recent analysis based on reinfection
rates after treatment with DHA–PQP or AL in moderate-to-high-
transmission areas in children estimated that 12% of cases could be
prevented by using DHA–PQP, and that using DHA–PQP as ﬁrst-
line treatment could save costs while averting more cases9. Here,
we additionally consider gametocytocidal effects, treatment in
adults, variations in transmission intensity and access to treatment
across malaria-endemic countries in Africa. DHA–PQP has a
weaker effect against gametocytes and infectivity to mosquitoes
than AL10,11, which may be due to less frequent dosing and a lower
total dose of the artemisinin component. In addition, lumefantrine
may inhibit parasite development in the mosquito12,13. Here we
develop and parameterize pharmacokinetic-pharmacodynamic
(PKPD) models for DHA–PQP and AL, which are then
embedded within a malaria transmission model. Second, we use
the model to simulate the impact and cost effectiveness of replacing
AL with DHA–PQP as ﬁrst-line treatment in malaria-endemic
countries in Africa, taking into account different transmission
patterns, access to treatment and health system costs. We estimate
that the difference in impact in terms of reducing clinical episodes
between the two treatments would be modest in most malaria-
endemic areas of Africa, but that DHA–PQP has a higher impact
in the majority of the population at risk. Where transmission is
very low, AL has the same or higher impact as DHA–PQP due to
its greater gametocytocidal effects. Despite the small difference in
the impact of the two drugs, the cost implications are substantial
given that the estimated cost per case averted by using a locally
appropriate treatment compares favourably with other malaria
control interventions.
Results
Pharmacodynamics of piperaquine and lumefantrine. The
duration and extent of protection provided by DHA–PQP and AL
drug regimens has not been characterized in detail. To estimate
this, we analysed data on reinfection after treatment of uncom-
plicated malaria with DHA–PQP or AL from randomized clinical
trials14,15. We incorporated published pharmacokinetic models;
piperaquine capillary blood concentrations were simulated8 based
on data from children in Africa aged 2–10 years. We used a
pharmacokinetic model of lumefantrine with a two-compartment
structure16. The artemisinin components have very short half-
lives of just a few hours so do not contribute to prophylaxis. Both
lumefantrine and piperaquine act against blood-stage infection.
We therefore modelled the protective effect of treatment as a
reduced probability of new blood-stage infection becoming
established in the presence of a given concentration of
antimalarial. The concentration-effect curve takes the form:
P ¼ b Pminþ 1 Pmin
1þ CC50
 k
0
B@
1
CA
where b is the infection probability (the probability of
an infectious bite leading to a slide-positive blood-stage
infection when drug concentration is zero), bPmin is the
infection probability at inﬁnitely high blood drug concentration,
C is the blood drug concentration, C50 is the blood drug
concentration that gives half the maximum reduction in the
infection probability and k determines the steepness of the
concentration-effect curve.
We simulated reinfection after treatment as in a previous
analysis17, incorporating age, heterogeneity in exposure to
mosquito bites and pre-erythrocytic immunity. The model was
ﬁtted to the proportion of individuals reinfected over time in the
clinical trials by varying the parameters of the concentration-
effect curves, which were assumed to be the same across sites, and
the entomological inoculation rate (EIR) in each site. We ﬁtted
the data from the different sites and trial groups simultaneously,
using Bayesian Markov Chain Monte Carlo methods with a
random walk Metropolis–Hastings algorithm to sample from the
posterior distribution.
The cumulative rate of PCR-conﬁrmed reinfection in the
clinical trial data was generally higher in children treated with AL
compared with DHA–PQP (Fig. 1), with the difference tending to
be larger in higher transmission sites due to more reinfection
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events. The best-ﬁtting model predictions from our PKPD model
were within the 95% conﬁdence intervals (CI) of the large
majority of data points (Fig. 1). The concentration at which each
antimalarial prevents 50% of new infections from successfully
establishing as blood-stage infections was estimated at
22.1 ngml 1 for piperaquine and 332.3 ngml 1 for lumefan-
trine (Fig. 2a,b; Table 1). In the study populations in which the
clinical trials were conducted, the mean number of days for which
piperaquine prevented 90% or more reinfections was 26.2
(range 13.6–45.0 days depending on dose–weight group) and
it prevented 50% or more reinfections for 29.4 days (range
16.4–48.8 days; Fig. 2c). Lumefantrine was estimated to provide
over 90% protection for 12.1 days (range 9.0–20.6 days) and
over 50% protection for 13.8 days (range 10.2–22.8 days; Fig. 2d).
The duration of protection provided by both drugs varied by
bodyweight, dose and age, but was particularly variable for
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Figure 1 | PKPD model ﬁt. Model predictions (lines) and cumulative PCR-conﬁrmed reinfection rates in clinical trial data in 1,651 individuals in six sites
(points with 95% CI). Green¼AL and blue¼DHA–PQP. Sites: a¼Nanoro, Burkina Faso; b¼Kiliﬁ, Kenya; c¼Manhic¸a, Mozambique; d¼Mbarara,
Uganda; e¼Ndola, Zambia14; and f¼Bobo-Dioulasso, Burkina Faso15.
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Figure 2 | PKPD results. Concentration-effect curves for piperaquine (a) and lumefantrine (b) estimated from model ﬁtting, with 95% CI. Piperaquine
concentrations relate to capillary measurements and lumefantrine concentrations to venous measurements. Probability of protection from reinfection over
time since the ﬁrst dose based on pharmacokinetic models: piperaquine (c,e) and lumefantrine (d,f), simulations in children o10 years in the clinical
trials (c,d) and in all age–weight groups based on Tanzanian bodyweight distribution (e,f). Probability of protection from reinfection over time since the ﬁrst
dose with piperaquine (g) or lumefantrine (h)—model ﬁts and 95% CI using a Weibull survival function instead of pharmacokinetic models.
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Table 1 | PKPD and reinfection model parameters.
Parameters Symbol Prior distribution Prior median
(95% interval)
Posterior estimate and
95% credible interval,
or ﬁxed value
Units Source
Fitted parameters, full PKPD model
Probability of reinfection as piperaquine
concentration tends towards inﬁnity
Pmin Beta a¼ 1, b¼ 15 0.0045 (0.0018, 0.2184) 0.0038 (0.0001–0.0210) — 19
Piperaquine capillary concentration that
gives half the maximum reduction in the
probability of blood-stage infection
C50 Half-normal,
mean¼0,
s.d.¼ 30 (absolute
values)
20.2 (0.9, 67.2) 22.1 (19.9–24.1) ngml 1 8
Piperaquine power parameter k Half-normal,
mean¼0, s.d.¼ 15
(absolute values)
10.1 (0.5, 33.6) 21.0 (9.5–40.7) — —
Probability of reinfection as lumefantrine
concentration tends towards inﬁnity
Pmin Beta a¼ 1, b¼ 15 0.0045 (0.0018, 0.2184) 0.0224 (0.0006–0.1017) — 19
Lumefantrine venous concentration at
which gives half the maximum reduction
in the probability of blood-stage infection
C50 Half-normal,
mean¼0,
s.d.¼ 500
(absolute values)
337.3 (15.6, 1121.2) 331.0 (229.2–543.4) ngml 1 51
Lumefantrine power parameter k Half-normal,
mean¼0, s.d.¼ 15
(absolute values)
10.1 (0.5, 33.6) 12.2 (2.6–34.3) — —
Annual EIR—Nanoro, Burkina Faso e Log-normal,
mean¼ log* (130),
s.d.¼0.7
130 (33, 513) 97.3 (66.2–145.6) ibpppy 14
Annual EIR—Kiliﬁ, Kenya e Log-normal,
mean¼ log(34),
s.d.¼0.7
34 (9, 135) 19.6 (11.7–31.6) ibpppy 14
Annual EIR—Manhic¸a, Mozambique e Log-normal,
mean¼ log(38),
s.d.¼0.7
38 (10, 150) 24.9 (16–39.3) ibpppy 14
Annual EIR—Mbarara, Uganda e Log-normal,
mean¼ log(14.5),
s.d.¼0.8
14.5 (3, 70) 19.8 (11.5–34.3) ibpppy 57,58
Annual EIR—Ndola, Zambia e Log-normal,
mean¼ log(6),
s.d.¼0.8
6 (1, 29) 41.1 (24.7–64.7) ibpppy 58,59
Annual EIR—Bobo-Dioulasso, Burkina Faso e Log-normal,
mean¼ log(117),
s.d.¼0.8
117 (24, 561) 25.2 (17.1–36.5) ibpppy 58
Fitted parameters: model of prophylaxis without PKPD (Weibull survival curve)
Piperaquine scale parameter l Half-normal,
mean¼0,
s.d.¼ 3,000
(absolute values)
84 (3.9, 280.2) 28.1 (23.6, 34.5) Days —
Piperaquine slope parameter w Half-normal,
mean¼0, s.d.¼ 15
(absolute values)
10.1 (0.5, 33.6) 4.4 (2.9, 7.6) — —
Lumefantrine scale parameter l Half-normal,
mean¼0,
s.d.¼ 3,000
(absolute values)
84 (3.9, 280.2) 10.6 (9.3, 13.1) Days —
Lumefantrine slope parameter w Half-normal,
mean¼0, s.d.¼ 15
(absolute values)
10.1 (0.5, 33.6) 11.3 (4.0, 32.2) — —
Annual EIR—Nanoro, Burkina Faso e Log-normal,
mean¼ log*(130),
s.d.¼0.7
130 (33, 513) 74.4 (48.7–111.5) ibpppy 14
Annual EIR—Kiliﬁ, Kenya e Log-normal,
mean¼ log(34),
s.d.¼0.7
34 (9, 135) 17.9 (10.9–28.7) ibpppy 14
Annual EIR—Manhic¸a, Mozambique e Log-normal,
mean¼ log(38),
s.d.¼0.7
38 (10, 150) 21.9 (14.5–33.2) ibpppy 14
Annual EIR—Mbarara, Uganda e Log-normal,
mean¼ log(14.5),
s.d.¼0.8
14.5 (3, 70) 16.5 (9.6–27.6) ibpppy 57,58
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piperaquine, in line with variable efﬁcacy results by dose group18.
The data on reinfection covered 42 days after treatment, while
piperaquine was estimated to give some protection after 42 days
in weight groups who have higher piperaquine exposures
(Fig. 2c,e). However, in these age groups, the curves after 42
days are informed by dose–weight groups in whom piperaquine
concentrations decline more quickly, reaching low levels
within 42 days. We extended pharmacokinetic simulations of
piperaquine and lumefantrine concentrations to all age groups
using published age–weight relationships, and pharmacokinetic
studies in adults, where available (Fig. 2e,f; Supplementary
Methods; Supplementary Fig. 2).
Since there is uncertainty in the pharmacokinetic models,
particularly in extrapolating to different populations and age
groups, we also undertook a simpler analysis without pharma-
cokinetics in which the probability of protection against
reinfection after treatment P was assumed to decline according
to a Weibull survival curve (see Methods). This analysis estimated
that the duration of protection at a level of 90% or higher was
16.8 days for piperaquine and 8.6 days for lumefantrine, and the
duration of protection at 50% or over was 25.8 and 10.2 days,
respectively (Fig. 2g,h). These are in line with the results of the
PKPD model, although the piperaquine protection declines more
gradually because it is an average of the weight-speciﬁc estimates
(Fig. 2c,d). Supplementary Table 1 gives further details of the
sensitivity analysis of the PKPD results.
AL and DHA–PQP have different effects on gametocytes and
onward transmission after treatment19. We assumed that patients
infected 1.85 times more mosquitoes when treated with DHA–PQP
than with AL based on a human-to-mosquito transmission study11.
Validation of transmission and treatment model. Using the
relationships between drug concentrations and post-treatment
prophylaxis estimated in the PKPD analysis, we simulated the
potential impact of using AL or DHA–PQP as ﬁrst-line treatment in
endemic populations. We used an existing age-structured individual-
based mathematical model, which describes the full transmission
cycle of the parasite between humans and mosquitoes, as well as
disease progression in humans, and has been detailed elsewhere17,20.
The model has been ﬁtted to extensive data on parasite prevalence
via microscopy and PCR and episodes of uncomplicated malaria by
age and transmission setting across Africa. It also incorporates
the impact of long-lasting insecticide-treated nets (LLINs). We
developed the model to include the estimated dose–weight-speciﬁc
post-treatment prophylactic proﬁles (Fig. 2e–h).
We ﬁrst validated our transmission model by comparing
simulations with data from a long-term trial in Tororo, Uganda,
in which children aged 4 months–1 year were randomized to
receive AL or DHA–PQP every time they presented with malaria
at health facilities and were followed up until age of 4 years21. The
rate of clinical episodes in the DHA–PQP group in the trial was
0.84 (95% CI 0.74–0.95) times the rate in the AL group. The
model-predicted rate ratio of clinical incidence, taking into
account the local transmission intensity in the trial area and the
seasonal variation, was 0.87, within the 95% CI of the trial
estimate. The rate ratio was not substantially affected by assuming
a high or low LLIN coverage.
Inﬂuence of transmission intensity and seasonality on treat-
ment impact. Generalized simulations of switching treatment
Table 1 (Continued )
Parameters Symbol Prior distribution Prior median
(95% interval)
Posterior estimate and
95% credible interval,
or ﬁxed value
Units Source
Annual EIR—Ndola, Zambia e Log-normal,
mean¼ log(6),
s.d.¼0.8
6 (1, 29) 32.7 (20.6–51.9) ibpppy 58,59
Annual EIR—Bobo-Dioulasso, Burkina Faso e Log-normal,
mean¼ log(117),
s.d.¼0.8
117 (24, 561) 20 (13.6-28.9) ibpppy 58
Fixed parameters
Age-related biting parameter r Fixed — 0.85 17
Age-related biting parameter a0 Fixed — 2920 Days
17
Variance in exposure to mosquito bites Fixed — 1.768 — 17
Infectiousness after AL treatment relative
to an untreated infection
Fixed — 0.05094 — 11,60
Infectiousness after DHA–PQP treatment
relative to an untreated infection
Fixed — 0.09434 — 11,60
Duration of treated infection Fixed — 5 Days 17
Duration of untreated infection Fixed — 195 patent infection
followed by 84 subpatent
infection
Days 17
Pre-erythrocytic immunity
Time during which immunity cannot be
boosted after a previous boost
ub Fixed — 4.44 —
17
Decay parameter db Fixed — 3650 Days
17
Infection probability in non-immunes bh Fixed — 0.637 —
17
Lowest infection probability at maximum
immunity relative to non-immunes
bmin Fixed — 0.500 —
17
Scale parameter IB0 Fixed — 57.89 —
17
Shape parameter q Fixed — 2.11 — 17
ibpppy, infectious bites per person per year; PKPD, pharmacokinetic-pharmacodynamic.
*Natural log.
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policy from AL to DHA–PQP were run to explore the impact in
areas with different initial transmission intensity (50, 15 and 5%
baseline slide prevalence of malaria in 2–10 year olds) and sea-
sonality in transmission (uniform over the year or strongly sea-
sonal withB90% of infectious bites occurring within 4 months).
Here we assumed that 80% of clinical cases would be treated with
AL, switching all treatment to DHA–PQP at a given time point.
Outcomes of cumulative number of clinical episodes prevented
and reductions in slide prevalence were assessed 5 years after the
change in treatment policy in all age groups, comparing this
with a continuation of the AL policy. In the scenarios considered,
DHA–PQP reduced transmission compared with AL, indicating
that its longer post-treatment prophylactic period was more
important than the higher gametocytocidal effect of AL (Fig. 3).
Reductions in transmission were higher in areas with high
initial transmission intensity due to the greater chance of
receiving an infectious bite during periods of post-treatment
prophylaxis. For example, in non-seasonal settings, an estimated
0.03 and 0.19 clinical episodes were prevented per person when
initial slide prevalence was 5 and 50%, respectively (Fig. 3a).
Approximately 82 and 26% of this impact is due to the direct
protection by the drug in the highest and lowest transmission
settings, respectively, the remainder being due to a community-
wide effect on transmission. Estimated impacts were always
higher in areas with seasonal variation in transmission. For
example, an estimated 0.19 episodes were prevented per person in
a non-seasonal setting with baseline slide prevalence of 50%
versus 0.56 episodes in a seasonal setting with the same total
annual clinical incidence.
Estimated impact of treatment across Africa. Transmission
model simulations were run at the resolution of the ﬁrst
administrative unit across Africa (Supplementary Fig. 3), using
three types of speciﬁc local data for each area: (1) the underlying
population demographic data22,23 combined with the slide
prevalence in 2010 (ref. 24) (Supplementary Fig. 3a), (2) the
seasonal pattern determined by high-resolution rainfall data25
(Supplementary Fig. 3b) and (3) intervention coverage, that is,
current access to treatment and LLIN coverage (Supplementary
Fig. 3c,d)7,26,27. We used a published analysis of treatment access
by administrative unit to obtain the estimated proportion of
fevers treated with an antimalarial, the proportion of these
antimalarials that are ACTs, and whether treatment is sourced in
the public versus private sector27. In each administrative unit, we
simulated transmission from 2000 to 2017, matching 2010
prevalence to the most recent Malaria Atlas Project map24. We
incorporated location-speciﬁc data on LLIN scale-up up to 2012
and assumed that coverage remained at the 2012 level in future
years. We simulated the introduction of either AL or DHA–PQP
as ﬁrst-line treatment at the beginning of 2012 and calculated the
cumulative clinical incidence over the next 5 years. In each case,
we assume that all ACTs taken are either AL or DHA–PQP. We
simulated various different scenarios about coverage of AL and
DHA–PQP in each area.
Assuming that the proportion of cases receiving an antimalarial
and ACT coverage remains at their current levels27 (Fig. 4a)
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Figure 3 | Generic model simulations. Model-simulated impact in all age
groups on clinical episodes and parasite prevalence of having DHA–PQP as
ﬁrst-line treatment versus AL over 5 years in low, medium and high
transmission settings with (red) and without (orange) seasonal variation in
transmission, assuming high treatment access (80% of cases are treated),
but no other interventions. Low, medium and high indicate baseline slide
prevalence levels before treatment change of 5, 15 and 50%, respectively, in
children aged 2–10 years in the non-seasonal setting. Seasonal settings
have the same baseline clinical incidence as the non-seasonal settings.
Absolute reductions (a,c) and percentage reductions (b,d) in the DHA–PQP
versus AL scenarios are shown.
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Figure 4 | Africa-wide simulations. Estimated impact of using DHA–PQP
versus AL as the ﬁrst-line treatment by ﬁrst administrative unit in malaria-
endemic areas of Africa. Cumulative numbers of clinical episodes prevented
5 years after changing treatment policy per 1,000 individuals of all ages,
under different coverage scenarios: (a) current ACT treatment rates in the
public sector only, (b) current ACT treatment rates in the public and private
sector, (c) current antimalarial treatment rates with scaled-up ACT
coverage to 100% and (d) scaled-up treatment access—80% of clinical
malaria cases receive ACT. Grey areas indicate no P. falciparum or a slide
prevalence o1% or no data.
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and that treatment policy change would only affect the public
sector, DHA–PQP had a modestly higher impact than AL in 64%
of the population at risk. In these populations, a median of 26
cases per 1,000 people (interquartile range (IQR): 15–43) were
averted in the 5 years after the policy change compared with the
scenario of using AL. Areas where DHA–PQP was predicted to
have the highest impact were those with high levels of
transmission, large seasonal variation in transmission and with
reasonable ACT coverage in the public sector; these included
Burkina Faso, southern Mali and northeast Mozambique, where
the number of cases averted was up to 100 per 1,000 people over
5 years. In a further 32% of the population at risk, there was
negligible difference (o0.5%) between the AL and DHA–PQP
scenarios. In some areas, this was simply due to low recorded ACT
coverage. In other areas such as the highlands of East Africa, there
was less impact due to low malaria transmission, meaning that
there is less beneﬁt of prophylaxis. In 4% of the population at risk,
AL had a slightly better impact than DHA–PQP; these were areas
with low endemicity, where there is almost no beneﬁt of
prophylaxis, but there is some beneﬁt of the greater
gametocytocidal action of AL. The difference was small, with a
median of 2.7 (IQR: 1.8–6.3) fewer cases per 1,000 over 5 years in
the AL compared with DHA–PQP scenario. We also ran a
subgroup analysis for countries that currently use AL as a ﬁrst-line
treatment28. An estimated 7.3 million clinical cases would be
averted over 5 years by switching to DHA–PQP, or 0.9% of total
cases (IQR across areas: 0.4–1.7%). This assumes that all ACTs
used were either AL or DHA–PQP.
Simulations, which assumed that a change in treatment policy
would cause a change in the ACTs used in the private as well as
public sector (Fig. 4b), showed, as would be expected, a larger
difference in impact between the two ACTs, particularly in
countries with signiﬁcant use of ACTs in the private sector, such
as Burkina Faso, Rwanda and Burundi. In countries with an AL
ﬁrst-line policy, the total estimated number of cases averted by
using DHA–PQP instead of AL over 5 years was 11.9 million,
1.4% of all cases. Impact on EIR and slide prevalence are shown
in Supplementary Figs 4 and 5. Due to uncertainty in estimates of
ACT coverage, we ran the analysis of policy change in public and
private sectors twice using two different sources of data: an
analysis by Cohen et al.27 and the World Malaria Report28. For
those areas where ACT coverage data were available from both
sources, the difference between DHA–PQP and AL was larger
using the World Malaria Report data due to higher net ACT
coverage estimates relative to local malaria case numbers, with an
estimated 2.2% of all cases averted by using DHA–PQP instead of
AL, as opposed to 1.4% of cases using the Cohen et al. estimates.
If ACT coverage were scaled up to 100% in both public and
private sectors, and the proportion of cases receiving an
antimalarial remained at current levels, the estimated difference
in impact between DHA–PQP and AL in countries currently
using AL increased to 33.5 million cases averted, 4.0% of the total
(Fig. 4c). The higher impact was marked in areas with low
reported current ACT coverage, for example, in Nigeria. If both
treatment access and ACT coverage were scaled up so that 80% of
clinical malaria cases received an antimalarial with 100% ACT
coverage, the impact of DHA–PQP increased to an estimated 57.6
million cases averted over 5 years, 7.4% of the total (Fig. 4d; IQR
across areas: 4.7–8.3%). Under these assumptions, the proportion
of the population at risk who experienced a positive impact of
DHA–PQP increased to 93%. The maximum impact range under
this scenario was 10–15% of clinical cases averted in high-
transmission areas with high levels of seasonal variation, such as
Burkina Faso. Eight percent of the population at risk had
estimated case reductions of410%. With equal treatment access
across areas, the strongest predictor of whether DHA–PQP would
have a greater impact than AL was transmission intensity. Sixty-
four percent of areas where AL had equal or better impact than
DHA–PQP had a slide prevalence of o5% in 2–10 year olds,
whereas 92% of areas with a positive impact of DHA–PQP had a
slide prevalence of 45%.
Cost effectiveness. We calculated the incremental cost-effective-
ness ratio in each area over a 5-year period based on the predicted
cumulative number of clinical malaria cases in all age groups with
DHA–PQP versus AL as ﬁrst-line policy. Our main cost-effec-
tiveness analysis focusses on the scenario with current treatment
access and ACT coverage in the public sector (Fig. 4a). In 64% of
the population at risk, DHA–PQP improved impact on trans-
mission but there was a higher cost of treatment due to slightly
higher unit costs of DHA–PQP compared with AL (Fig. 5;
Table 2). In these areas, the median incremental cost per case
averted over 5 years after changing treatment policy was $1.94
(IQR: $1.20–2.75). In areas with negligible difference between the
clinical incidence under the DHA–PQP scenario and the AL
scenario, the cost was on average 7% less in the scenario where
AL was used. In 0.4% of the population at risk, DHA–PQP
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Figure 5 | Cost effectiveness. (a) Total cases averted and total difference in costs of treatment in USD over 5 years in 492 administrative areas of
Africa, comparing use of DHA–PQP with AL. (b) Incremental cost-effectiveness ratios: cost per case averted by introducing DHA–PQP as the ﬁrst-line
treatment instead of AL, averaged over 5 years by ﬁrst administrative unit. Blue scale¼ areas where DHA–PQP has a positive impact on averting cases but
higher overall cost than AL, red¼AL dominates (averts more cases with lower costs than DHA–PQP), yellow¼DHA–PQP dominates. Grey areas
indicate no P. falciparum or P. falciparum slide prevalence o1% or no data.
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reduced both the total number of cases and total costs. This
occurred where the case reduction was sufﬁciently high and in
countries where the cost of an outpatient visit is relatively high
(4$7 per appointment), so that antimalarial costs constituted
only a small part of the total cost of treating a malaria case. These
were areas in Gabon, Equatorial Guinea and Namibia. The cost
was on average 0.7% less than that in the scenario where AL was
used. Where clinical incidence was higher under the DHA–PQP
scenario, a DHA–PQP policy was not incrementally cost effective.
In these areas, the median difference in case numbers between the
AL and DHA–PQP scenarios was 1.0%, while the cost was 11%
cheaper with AL than DP. In the scenario with scaled-up access to
treatment (80% of cases receive an ACT), areas with 410% case
reductions had an estimated cost reduction of 4% under the
DHA–PQP scenario versus the AL scenario due to fewer out-
patient visits.
Drug choice versus treatment access and coverage. We also
estimated the impact of increasing ACT coverage and access to
treatment on total clinical burden to determine the importance of
these factors relative to the drug choice between DHA–PQP
versus AL. In countries which currently use AL as a ﬁrst-line
treatment, increasing AL coverage to 100% among patients who
receive an antimalarial, while assuming no change in the pro-
portion of cases receiving an antimalarial, predicts that 2.5 mil-
lion (0.3%) cases would be averted compared with the scenario of
keeping ACT coverage at current levels. This impact is therefore
lower than switching to DHA–PQP and keeping current ACT
coverage the same (see above: 7.3 million cases averted (0.9%)).
However, if the proportion of cases that receive an antimalarial
increased to 80% in these countries and all patients received AL,
an estimated 59.8 million cases would be averted (7.2% of total;
compared with 117.4 million total averted under a DHA–PQP
policy).
Discussion
Using two common ﬁrst-line treatments for malaria in Africa—
AL and DHA–PQP—as examples, our analysis demonstrates the
complexity of assessing the potential impact and cost effectiveness
of new treatments in settings that vary in malaria epidemiology,
access to care and associated healthcare costs. While our analysis
was not intended to recommend a particular antimalarial, for
which other factors including the potential side effects, risk of
resistance and patient adherence are also important, it does
illustrate the potential advantages and disadvantages of key drug
properties including their gametocytocidal efﬁcacy and duration
of post-treatment prophylaxis relative to the drug cost.
Overall, we predict a modest average reduction in clinical
malaria incidence in almost two-thirds of the simulated
population at risk in endemic African settings under current
estimates of ACT access if ﬁrst-line treatment is switched to
DHA–PQP due to its longer post-treatment prophylaxis. The
beneﬁt was greater in high-transmission areas. Our estimates of
10–15% reduction in cases in such areas when treatment access is
high are in line with the Pfeil et al.9 estimate of 12% of cases
averted by using DHA–PQP as ﬁrst-line treatment rather than AL
in children in moderate-to-high-transmission areas. However,
in the majority of endemic areas, our estimated impact of
DHA–PQP is lower than that of Pfeil et al. due to considering
lower-transmission areas, lower treatment access and treatment
in adults who have greater immunity. A similar impact of
post-treatment prophylaxis would be predicted with other long-
acting partner drugs, such as meﬂoquine. However, in about
a third of the population at risk living in lower-endemicity
areas, the advantage of a longer prophylactic period after
DHA–PQP was less important. Because AL has a larger impact
on transmissibility, AL either produced a better or similar
reduction in clinical incidence.
Although the difference in impact between the drug regimens
was generally small, there were important cost implications given
the current lower price of AL compared with DHA–PQP. The
incremental cost per case averted in areas where there was a
beneﬁt of DHA–PQP was low given that a new ﬁrst-line
treatment would be provided through existing primary-care
facilities, with a median of $1.94. This compares with a median
cost per case averted of other malaria control interventions
(under a provider perspective) of $24 (range $2.29–71) for
insecticide-treated nets, $19 (range $0.54–267) for indoor residual
spraying29, $0.68–2.27 for intermittent preventive treatment of
infants with SP30 and $64.93–208.69 for seasonal intermittent
preventive treatment31. However, we did not factor in the cost of
changing treatment policy as this is difﬁcult to quantify and
would vary across countries. As in the previous Pfeil et al. cost-
effectiveness analysis, DHA–PQP could in some areas reduce
both the total number of cases and total costs; however, our
analysis found that this applies only in a very small number of
areas (0.4% of the population at risk). In areas where AL has a
similar or better impact, using this less-expensive drug saves on
treatment costs. Antimalarial prices ﬂuctuate and we did not take
into account of this variation. We did not include the cost of co-
administering AL with milk or other fatty substance, which is
required to aid absorption, and may be provided by public health
facilities at B$0.48 per treatment course32.
Perhaps, surprisingly, the better gametocytocidal effect of AL
did not produce an improved impact in our simulations in many
areas when compared with a drug with a longer half-life. Both
regimens are highly efﬁcacious in rapidly clearing parasites from
the blood and hence at reducing transmission. Therefore,
although the infectivity may be around 2-fold higher after
DHA–PQP, both AL and DHA–PQP reduce the average duration
of infectiousness more than 50-fold compared with untreated
infections (Table 1). Given that only a proportion of malaria
infections in the population are treated, the majority of
transmission arises from untreated infections, and therefore this
small difference in infectiousness among treated individuals
rarely has a measurable impact in our model. This result is
dependent on our assumptions about the relative infectiousness
of treated and untreated cases. Our parameters underlying this
are derived from a combination of studies11,33–35. Sensitivity
analysis indicates that assuming a higher infectivity of treated
Table 2 | Cost input data.
Item Patient
weight (kg)
Patient
age (years)*
Cost in
US$
Reference
AL (one full
treatment course)
5–14 0–4 0.42 Novartis price
to GF AMFmw
15–24 5–10 0.84
25–34 11–14 1.25
35þ 15þ 1.52
DHA–PQP (one full
treatment course)
5–13 0–3 0.67 Sigma-Tau price
to GF AMfMz
13–24 4–9 0.93
24–36 10–14 1.46
36–75 15þ 1.96
RDT (one unit) — — 1.5 61
AL, artemether–lumefantrine; DHA–PQP, dihydroartemisinin–piperaquine; GF AMFm, Global
Fund Affordable Medicines Facility-malaria; RDT, rapid diagnostic test.
*Range based on average age–weight relationship in endemic areas (see Methods).
wNiger public health sector, November 2012.
zCambodia public health sector, April 2012.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6606
8 NATURE COMMUNICATIONS | 5:5606 |DOI: 10.1038/ncomms6606 |www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
individuals compared with untreated individuals (but the same
relative infectiousness of DHA–PQP patients versus AL patients)
would slightly increase the range of settings in which AL has a
better impact than DHA–PQP (Supplementary Fig. 6).
Several countries (Ghana, Kenya, Nigeria and Senegal) are
introducing multiple ﬁrst-line therapies for malaria to help
combat drug resistance. Given that there are ﬁve recommended
ACTs, there is still scope to choose regimens that suit the local
epidemiology as long as partner drug resistance does not limit the
options. For example, AS–SP, AS–MQ and DHA–PQP are all
longer-acting regimens36. The spatial scale over which multiple
ﬁrst-line therapies should be implemented remains unclear;
however, if implemented regionally, longer-acting ACTs could be
targeted to areas of higher transmission, while lower-transmission
areas could receive ACTs optimal in terms of cost or
gametocytocidal effects. This would be consistent with wider
policy moves away from a ‘one size ﬁts all’ approach to malaria
control.
While our analysis ﬁnds that choosing a locally appropriate
treatment is important, impact is limited by current low access
to treatment in some areas. In countries which currently have
an AL ﬁrst-line policy, we estimate that increasing access so
that 80% of cases received AL would avert over sevenfold more
cases than switching policy from AL to DHA–PQP with no
change in current coverage levels. Likewise, the impact of an
appropriate treatment is dramatically increased when coverage
is high.
Resistance and patient adherence are additional important
considerations when selecting treatment policy, which we did not
include in our analysis. Piperaquine resistance is not reported in
Africa, but has been reported in Asia37,38,39. The long half-life of
the drug may make resistant parasites spread more quickly than
any lumefantrine-resistant parasites40. Clinical resistance to
lumefantrine has not been ofﬁcially conﬁrmed, although there
is likely to be cross-resistance with meﬂoquine41–43. Patient
adherence to the treatment regimen is likely to be better with
fewer doses and a simpler regimen: on this metric, the three-dose
DHA–PQP regimen has an advantage over the six-dose AL
regimen44. Furthermore, the need for sufﬁcient fat intake to
optimize AL absorption may lead to reduced efﬁcacy and a
shorter prophylactic period for lumefantrine45.
Our analysis made a number of simplifying assumptions; in
particular we assumed that treatment was only taken by
symptomatic malaria cases. In reality, lack of laboratory diagnosis
means that antimalarials are often taken by individuals with
either asymptomatic or no parasitaemia. This treatment also has
an impact on transmission through reducing transmission from
asymptomatic cases and providing prophylaxis. Sensitivity
analysis indicates that we may therefore underestimate the
difference in impact of the two drugs (Supplementary Fig. 7).
However, with improved use of and adherence to the results from
rapid diagnostic tests, uninfected individuals may be less likely to
receive treatment in the future. In several countries, ACTs are
only given to conﬁrmed cases. Treatment among uninfected
individuals is likely to vary by endemicity and age as well as
treatment access. Further work is needed to deﬁne these patterns.
Second, we did not include the possibility that long-acting drugs
could suppress parasite density in new infections without
completely clearing them, so that individuals may still transmit
if they have a subpatent infection acquired during the elimination
period of the drug. We were not able to assess this in the absence
of more sensitive molecular detection of reinfection. Third, while
we used the most recent available survey data, for some countries
this is out of date.
Increasing access to ACTs remains the most important overall
goal with regards to treatment for malaria control. However, with
ﬁve different ACTs to choose from, our analysis suggests
that choosing an appropriate treatment for the local area often
results in a more incrementally cost-effective intervention
than vector control. The longest-acting regimens have high
impact in areas with higher transmission, particularly when
there is seasonal variation. In areas of lower transmission
(baseline slide prevalence o5% in 2–10 year olds), we ﬁnd
that there is less advantage of investing in a long-acting
drug regimen and here effective, cheaper drug regimens could
be prioritized. More generally, our analysis suggests that there is
only a small additional beneﬁt to increasing the gametocytocidal
action of a ﬁrst-line treatment above the level achieved by
current ACTs, when most transmission arises from untreated
cases. Considering the relative beneﬁts of different drug actions
could aid policy makers and drug developers in prioritizing
investment.
Methods
Ethics statement. All data analysis conducted during this research was secondary
and used studies that had obtained ethical approval previously from the appro-
priate organizations. All data were anonymized before being provided to
investigators.
Data. Data were from two randomized clinical trials of DHA–PQP and AL in six
different African sites, whose participants were children 40.5 years with P. falci-
parum mono-infection (1,651 individuals with 14,241 observations)14,15.
Individuals were tested for parasitaemia up to day 42 after treatment. Insecticide-
treated nets were given to patients in some sites, which was taken into account in
our analysis (see below). We excluded individuals with recrudescent parasitaemia,
since reinfection status could not be assessed. We also excluded those who did not
follow the trial protocol and those410 years old (see Supplementary Methods for
details of inclusion criteria).
PKPD models. We categorized individuals into groups according to site, body-
weight (starting at 5 kg, individuals are grouped by 2 kg increments up to 27 kg,
which in turn determines dose) and exposure. We simulated the pharmacokinetics
of piperaquine and lumefantrine in each of these groups using the mean body-
weight and dose in the group and existing models8,16. When extending simulations
to adults, we used a published pharmacokinetic model of venous piperaquine
concentrations46 to estimate capillary concentrations in adults8. This provided very
high estimates of protection for piperaquine in adults (442 days of 450%
protection; Fig. 2e). Since the relationship between venous and capillary
concentrations is variable, and the PK model for adults was based on a small PK
study in women in Thailand, it was uncertain how representative these would be of
an adult population in Africa. Therefore, we set the adult post-treatment proﬁle to
equal that of the non-PK-based analysis in children (Fig. 2g) and the outlying
proﬁle in Fig. 2e was not used. Lumefantrine pharmacokinetics are ideally
described using a model with at least two compartments16. There is not yet such a
model ﬁtted to pharmacokinetic data in children in Africa. We therefore used a
pharmacokinetic model of lumefantrine based on data in pregnant women in
Asia16 and adapted the model parameters to match a published pharmacokinetic
data set in African children47 as follows. We started with the original parameter
values, then assumed the following parameters to be directly proportional to
bodyweight: the central volume of distribution, the clearance rate from the central
compartment, the intercompartmental clearance rate and the peripheral volume of
distribution. We simulated the three dose groups in the pharmacokinetic study47
using their mean bodyweights. The predicted venous plasma concentration across
dose groups was ﬁtted to the data using least squares, by further scaling the two
clearance parameters by a single allometric parameter, which was estimated
(Supplementary Fig. 1). We included interindividual variation in the
pharmacokinetic parameters and compared this with the population average
results. For the piperaquine simulations, we used the random effects ﬁtted in the
original model and for the lumefantrine simulations, we assumed the same percent
coefﬁcient of variation (CV) on each parameter as in the original ﬁt of the model to
the data from adults (where CV ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃexp meanð Þ 1p ). We numerically integrated
over the random effects using multivariate Gauss–Hermite quadrature with four
quadrature points per parameter.
We also estimated protection against reinfection P after treatment as a Weibull
survival curve without any pharmacokinetic assumptions, assuming no difference
by age or weight:
P ¼ e t=lð Þw
where t is time, l is a scale parameter and w controls the slope of the curve. l and w
were estimated for each antimalarial regimen.
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We simulated reinfection after treatment as described17 in each dose–weight
group according to the local age structure22, assuming a constant force of infection
over time. We also explored using a seasonally varying EIR speciﬁc to each of the
study sites, based on rainfall pattern as done previously25. Exposure to bites was
assumed to be reduced by 50% for those sites where participants were given an
insecticide-treated net at recruitment into the trial48,49. If parasites emerging from
the liver survive, we assumed a 3.5-day time lag50 until they become detectable by
microscopy. During model ﬁtting, all available individual observations were used to
calculate the Binomial log likelihood of the model given the probability of
reinfection during a time interval since the individual was last tested, for each
dose–weight group.
We used log-normal prior distributions for the annual EIRs in each site based
on values in the literature where available (Table 1). For three sites, EIR data were
not available, so the EIR was estimated from slide prevalence based on a published
relationship17 and the prior distribution was assigned a larger s.d. to allow for
greater uncertainty (Table 1). Without a reasonably informative prior, the EIR is
difﬁcult to distinguish from the concentration-effect curve.
Half-normal prior distributions with large variances were used for the
pharmacodynamic parameters C50 and k (Table 1). The C50 prior distributions
were informed by clinical trials, which found a cut-off on the day 7 concentrations
at which subsequent reinfection was more likely, but were only weakly informative
to cover the plausible biological range8,51. The infection probability at maximum
drug concentration was constrained to be small for both piperaquine and
lumefantrine, since there is currently no signiﬁcant documented failure of either of
these drugs in Africa19 (Table 1).
Model simulations. We used an existing age-structured individual-based
mathematical model17,20 and modiﬁed this to include PKPD. We validated our
model against a trial in Tororo, Uganda, comparing AL with DHA–PQP52. In
simulations of this setting, we matched the slide prevalence according to Malaria
Atlas Project 2010 estimates and the treatment intake as observed in the trial
(6.4 treatments per person-year in the AL arm and 5.3 in the DHA–PQP arm).
We simulated clinical incidence in the 0.5- to 4-year old age group over the
3.5 years of the intervention. Simulated coverage with LLINs in the community
was varied.
In the Africa-wide simulations, the proportion of symptomatic malaria
infections that are treated with effective antimalarials is an important parameter for
determining treatment impact. Data from Demographic and Health Surveys53 on
the proportion of fevers that are treated with a speciﬁc type of antimalarial in the
public versus private sector has recently been aggregated and analysed from each
country and administrative unit27. Direct data were available for children under 5
years of age for 421 administrative units and were standardized for the month of
survey. A relationship between the rate of treatment in children under 5 and those
aged over 5 was determined by the authors from 61 surveys of treatment rates in all
ages. We assumed that the probability of treatment of fever cases with antimalarials
was a good estimate of the probability of a symptomatic malaria case getting an
antimalarial. We modelled only treatment taken by symptomatic malaria cases (not
presumptive treatment taken by uninfected individuals). Symptomatic case
incidence by age, time point and location is simulated by the existing transmission
model.
We simulated the following scenarios about coverage of AL and DHA–PQP in
each area:
1. The proportion of cases receiving an antimalarial and ACT coverage remains at
their current level and we assume that only public sector treatment is switched
from AL to DHA–PQP.
2. The proportion of cases receiving an antimalarial and ACT coverage remains at
their current level and we assume that a change in national treatment policy
would cause a change in the public and private sectors.
3. Scaled-up ACT coverage: the proportion of cases receiving an antimalarial
remains at current levels but ACT coverage increases to 100% in public and
private sectors and a change in national treatment policy operates in both
sectors.
4. Scaled-up treatment access and ACT coverage: 80% of clinical malaria cases
receive an antimalarial, with 100% ACT coverage (through either the public or
private sector), and the switch to DHA–PQP occurs in both public and private
sectors.
We excluded areas where the prevalence was under 1% from our analysis
because the probability of local elimination of transmission in our stochastic model
can skew the results. We used a population size of 10,000 as standard, and 100,000
in areas where slide prevalence was o10%, to smooth out stochasticity.
Cost effectiveness. We calculated the unit cost per uncomplicated malaria case
treated as the sum of the cost of the antimalarial54, the country-speciﬁc unit cost of
an outpatient health facility visit55 and the cost of a rapid diagnostic test (Table 2).
The unit cost of the antimalarial varies by dose and was calculated according to the
number of cases occurring in each dose group, based on age-speciﬁc clinical
incidence from the model and population age structure. All costs and health
beneﬁts were discounted annually at a rate of 3%56.
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